Readers will no doubt be aware that U.S. President Trump has been vocal in his criticism of the pharmaceutical industry in the U.S., and has taken measures to address an imbalance in prices charged
Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis.
This news is powered by Seeking Alpha 
